131 related articles for article (PubMed ID: 16155120)
1. An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer.
Sakamoto J; Hamada C; Rahman M; Kodaira S; Ito K; Nakazato H; Ohashi Y; Yasutomi M
Jpn J Clin Oncol; 2005 Sep; 35(9):536-44. PubMed ID: 16155120
[TBL] [Abstract][Full Text] [Related]
2. An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer.
Sakamoto J; Kodaira S; Hamada C; Ito K; Maehara Y; Takagi H; Sugimachi K; Nakazato H; Ohashi Y;
Oncol Rep; 2001; 8(3):697-703. PubMed ID: 11295105
[TBL] [Abstract][Full Text] [Related]
3. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.
Sakamoto J; Hamada C; Yoshida S; Kodaira S; Yasutomi M; Kato T; Oba K; Nakazato H; Saji S; Ohashi Y
Br J Cancer; 2007 Apr; 96(8):1170-7. PubMed ID: 17375049
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Sakamoto J; Hamada C; Kodaira S; Nakazato H; Ohashi Y
Jpn J Clin Oncol; 1999 Feb; 29(2):78-86. PubMed ID: 10089948
[TBL] [Abstract][Full Text] [Related]
5. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
6. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Sargent DJ; Wieand HS; Haller DG; Gray R; Benedetti JK; Buyse M; Labianca R; Seitz JF; O'Callaghan CJ; Francini G; Grothey A; O'Connell M; Catalano PJ; Blanke CD; Kerr D; Green E; Wolmark N; Andre T; Goldberg RM; De Gramont A
J Clin Oncol; 2005 Dec; 23(34):8664-70. PubMed ID: 16260700
[TBL] [Abstract][Full Text] [Related]
7. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
9. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
de Gramont A; Hubbard J; Shi Q; O'Connell MJ; Buyse M; Benedetti J; Bot B; O'Callaghan C; Yothers G; Goldberg RM; Blanke CD; Benson A; Deng Q; Alberts SR; Andre T; Wolmark N; Grothey A; Sargent D
J Clin Oncol; 2010 Jan; 28(3):460-5. PubMed ID: 20008641
[TBL] [Abstract][Full Text] [Related]
10. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
Sargent D; Sobrero A; Grothey A; O'Connell MJ; Buyse M; Andre T; Zheng Y; Green E; Labianca R; O'Callaghan C; Seitz JF; Francini G; Haller D; Yothers G; Goldberg R; de Gramont A
J Clin Oncol; 2009 Feb; 27(6):872-7. PubMed ID: 19124803
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
Watanabe M; Nishida O; Kunii Y; Kodaira S; Takahashi T; Tominaga T; Hojyo K; Kato T; Niimoto M; Kunitomo K; Isomoto H; Ohashi Y; Yasutomi M
Int J Clin Oncol; 2004 Apr; 9(2):98-106. PubMed ID: 15108041
[TBL] [Abstract][Full Text] [Related]
12. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
13. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
[TBL] [Abstract][Full Text] [Related]
14. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
Oba K; Paoletti X; Alberts S; Bang YJ; Benedetti J; Bleiberg H; Catalano P; Lordick F; Michiels S; Morita S; Ohashi Y; Pignon JP; Rougier P; Sasako M; Sakamoto J; Sargent D; Shitara K; Cutsem EV; Buyse M; Burzykowski T;
J Natl Cancer Inst; 2013 Nov; 105(21):1600-7. PubMed ID: 24108812
[TBL] [Abstract][Full Text] [Related]
15. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
Sargent DJ; Patiyil S; Yothers G; Haller DG; Gray R; Benedetti J; Buyse M; Labianca R; Seitz JF; O'Callaghan CJ; Francini G; Grothey A; O'Connell M; Catalano PJ; Kerr D; Green E; Wieand HS; Goldberg RM; de Gramont A;
J Clin Oncol; 2007 Oct; 25(29):4569-74. PubMed ID: 17876008
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Figueredo A; Fine S; Maroun J; Walker-Dilks C; Wong S
Cancer Prev Control; 1997 Oct; 1(4):304-19. PubMed ID: 9765754
[TBL] [Abstract][Full Text] [Related]
17. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer.
Iwagaki H; Tanaka N; Esato K; Kaibara N; Sano K; Dohi K; Nakamura T; Nakasato H; Orita K
Anticancer Res; 2000; 20(5C):3727-34. PubMed ID: 11268446
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
